BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

29 articles for MF Brown

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Siderophore receptor-mediated uptake of lactivicin analogues in gram-negative bacteria.EBI
Pfizer
Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents.EBI
Pfizer
Structure-activity relationships and hepatic safety risks of thiazole agonists of the thrombopoietin receptor.EBI
Pfizer
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.EBI
Pfizer
Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI
Pfizer
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.EBI
Pfizer
The identification of orally bioavailable thrombopoietin agonists.EBI
Pfizer
Piperazinyl CCR1 antagonists--optimization of human liver microsome stability.EBI
Pfizer
Novel CCR1 antagonists with improved metabolic stability.EBI
Pfizer
Potent small molecule CCR1 antagonists.EBI
Pfizer
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.EBI
Pfizer
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).EBI
Pfizer
N-carbamoyl analogs of Zafirlukast: potent receptor antagonists of leukotriene D4.EBI
Pfizer
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.EBI
Pfizer
Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious gram-negative infections.EBI
Pfizer
Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.EBI
Pfizer
BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDSBDB
Lycia Therapeutics
NOVEL COMPOUNDS COMPRISING A NEW CLASS OF TRANSTHYRETIN LIGANDS FOR TREATMENT OF COMMON AGE-RELATED COMORBIDITIESBDB
Columbia University
Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseasesBDB
University of Washington Through Its Center For Commercialization
Inhibitors of bruton's tyrosine kinaseBDB
Hoffmann-La Roche
Spiro-cyclic amine derivatives as S1P modulatorsBDB
Abbvie
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBDB
Boehringer Ingelheim International
Overview of the SAMPL5 host-guest challenge: Are we doing better?BDB
University of California San Diego
Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereofBDB
Arena Pharmaceuticals
Substituted azoanthracene derivatives and intermediates for preparation thereofBDB
Vtv Therapeutics
Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor.BDB
Cnrs Upr 9023
Analyzing airway inflammation with chemical biology: dissection of acidic mammalian chitinase function with a selective drug-like inhibitor.BDB
University of Edinburgh